X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
Provided By GlobeNewswire
Last update: Nov 13, 2024
Mavorixafor durably and meaningfully elevated participants’ mean absolute neutrophil counts (ANC)
Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal levels
Read more at globenewswire.com3.725
-0.02 (-0.67%)
Find more stocks in the Stock Screener
XFOR Latest News and Analysis
9 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
